Judicial Insight
Back to feed
Judgment for plaintiff (Genentech wins enforcement of )CivilTrial court

Genentech, Inc. v. Novartis Pharma Ag

Court
District Court, District of Columbia
Decided
Oct 13, 2026
Docket
Civil Action No. 2025-1783
Judges
Judge Christopher R. Cooper
Detailed analysis & 3-line summary

AI breakdown

Analyzed Oct 13, 2026

Where this case stands

  1. This decision ·

    Judgment for plaintiff (Genentech wins enforcement of )

  2. This is the first court to decide the case, so there's no lower-court ruling.

TL;DR

  1. 1Genentech wants the court to enforce an arbitration ruling against Novartis about licensing issues.
  2. 2The court ruled to recognize and enforce the .
  3. 3The key reason was that the clearly outlined the licensing terms and costs.

Key issues

  1. 1

    Should the court recognize and enforce the ?

    Holding · Yes, the court upheld the arbitration ruling as valid.

Why it matters

This case affects the licensing agreements between biotech companies and how arbitration rulings are enforced in court.

The AI breakdown is a reading aid, not legal advice. Always check the opinion for the exact wording.

If you were the judge?

Genentech wants arbitration award enforced against Novartis. Can the court do it?

  1. 1Genentech says it won a binding arbitration decision on April 14, 2025, against Novartis about product licenses.
  2. 2They claim that Novartis is incorrectly saying Genentech violated their licensing agreements concerning the product Vabysmo®.
  3. 3Genentech is now asking the court to enforce the arbitration decision, which includes Novartis paying over $17 million in costs and confirming their interpretation of the licensing terms.

Should the court enforce the arbitration decision against Novartis?

Vote to earn 10 Verdict Points

Parties

  • Plaintiff

    Genentech, Inc.

  • Defendant

    Novartis Pharma Ag

Roles are inferred from the case caption.

Opinion of the court
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA GENENTECH, INC., Petitioner, v. Case No. 25-cv-1783 (CRC) NOVARTIS PHARMA AG, Respondent. ORDER The matter before the Court is Petitioner Genentech, Inc.’s (“Genentech”) Petition to Recognize and Enforce Foreign Arbitral Award for an order and judgment recognizing and enforcing the final, binding arbitration award (the “Final Award”) against Respondent Novartis Pharma AG (“Novartis”) rendered on April 14, 2025. Upon review of Petitioner’s [1] Petition to Recognize and Enforce Foreign Arbitral Award, Respondent’s [24] Response to Petition to Recognize and Enforce Foreign Arbitral Award, and Petitioner’s [25] Reply in Further Support of Petition to Recognize and Enforce Foreign Arbitral Award, it is hereby ORDERED that the Final Award in its entirety is recognized and enforced pursuant to 9 U.S.C. § 207. It is further ORDERED that judgment is entered in favor of Genentech and against Novartis in accordance with the Final Award in its entirety, including but not limited to: (i) DECIDING AND DECLARING that Vabysmo® (faricimab) is not a Licensed Product under the License and Collaboration Agreements (“LCAs”); (ii) CONCLUDING that the fragment that is licensed under the LCAs is the stand alone ranibizumab: Vabysmo® (faricimab), or the VEGF-binding arm thereof, are not covered by the LCAs; (iii) DENYING Novartis’s claim that Genentech has breached and will continue to breach the LCAs by encroaching on Novartis’ exclusive Territory, including by seeking regulatory approval of, using, selling, importing, and/or promoting Vabysmo® in countries outside the United States; (iv) ORDERING Novartis to pay to Genentech the costs it incurred for the arbitration, including attorneys’ fees, which amounts Novartis has paid, as follows: a. US$ 584,250 for the advance on the fees and expenses of the arbitrators and the ICC administrative expenses fixed by the Court; b. US$ 17,255,928.62 for the reasonable legal and other costs incurred for the arbitration; c. interest on these amounts at the rate of 9% annually from the date of the Final Award until full and final payment, subject to any order by an enforcement court applying its own rules to post-judgment interest. SO ORDERED. CHRISTOPHER R. COOPER United States District Judge Date: October 13, 2026 2
View on CourtListener